Bristol Myers Squibb Co. has described proteolysis targeting chimera (PROTAC) compounds comprising a E3 ubiquitin ligase-binding moiety coupled to a proto-oncogene tyrosine-protein kinase receptor Ret (RET; CDHF12; PTC) targeting moiety through a linker reported to be useful for the treatment of non-small-cell lung cancer.
Shenzhen Zhongge Biotechnology Co. Ltd. has discovered NLRP3 inflammasome inhibitors reported to be useful for the treatment of cancer, liver, cardiovascular, inflammatory, renal, metabolic and neuroinflammatory disorders.
OS Therapies Inc. has announced promising data in animal models of ovarian cancer for its first therapeutic candidate developed based upon its proprietary tunable antibody-drug conjugate (tADC) platform.
The newest data show increased survival times for heavily pretreated patients receiving Briacell Therapeutics Corp.’s breast cancer treatment. The company’s phase II results produced positive overall survival data using the cell-based immunotherapy Bria-IMT to treat late-stage metastatic breast cancer.
More than three months ago, investors first learned that ivonescimab, a PD-1/VEGF-targeting bispecific antibody from Summit Therapeutics and Akeso Pharmaceuticals Inc., bested Keytruda (pembrolizumab) in PD-L1-positive non-small-cell lung cancer (NSCLC). At the 2024 World Conference on Lung Cancer over the weekend, Summit rolled out detailed data from the phase III Harmoni-2 trial, which included a nearly doubling of progression-free survival for ivonescimab compared to Merck & Co. Inc.’s established blockbuster drug.
Technological breakthroughs are changing the biopharmaceutical landscape and forcing regulators to think on their feet and facilitate (not impede) innovation, experts said at the Global Bio Conference (GBC) 2024. “Regulatory speed and agility are necessary amid emergencies to cater to unmet medical needs,” Choong May Ling, CEO of Singapore’s Health Sciences Authority, told audience members in Seoul, South Korea.
Asia Pacific is the fastest growing region for health care spending, and by 2030 APAC will account for more than 20% of global health care spending, Tom Lawry, managing director of Second Century Tech told the APACMed Forum 2024 conference held in Singapore, Sept 5-6.
South Korean artificial intelligence-based drug developer Pharos Ibio Co. Ltd. said that the Ministry of Food and Drug Safety (MFDS) granted an orphan drug designation for PHI-101, a second-line therapy for acute myeloid leukemia (AML).
IRCCS San Raffaele, Universita Degli Studi Di Perugia and Universita Vita-Salute San Raffaele have jointly developed new oxysterols receptor LXR-α (NR1H3; LXRA) and/or LXR-β (NR1H2; LXRB) antagonists reported to be useful for the treatment of cancer, inflammatory and immunological disorders.
RSS
